Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Nicholas Bracciano

Psychiatry Milwaukee, WI Medical Doctor

NPI 1497140453 CMS profile 8192875

10012 W Capitol Dr Ste 101, Milwaukee, WI 53222

Open in the dashboard

General payments

$2,370

124 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicholas Bracciano of Milwaukee, WI is reported in the CMS Open Payments database as having received $2,370 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $280 13
2024 General $430 20
2023 General $505 27
2022 General $571 32
2021 General $388 22
2020 General $196 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicholas Bracciano
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Nicholas Bracciano were reported at $280. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Nicholas Bracciano Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $196 $119 $36–$372 $114
2021 $388 $143 $43–$576 $132
2022 $571 $153 $50–$590 $149
2023 $505 $170 $56–$651 $160
2024 $430 $179 $57–$673 $164
2025 $280 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $420 25 payments
  2. Alkermes, Inc. $417 18 payments
  3. Lundbeck LLC $318 16 payments
  4. Otsuka America Pharmaceutical, Inc. $162 8 payments
  5. Indivior Inc. $150 7 payments
  6. Orexo US, Inc. $140 9 payments
  7. Bausch Health US, LLC $119 6 payments
  8. Neurocrine Biosciences, Inc. $92 5 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $83 5 payments
  10. Janssen Pharmaceuticals, Inc $80 4 payments
  11. Other $389 21 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $2,370 124 payments
Products named General payments · program years 2020–2025
  1. LYBALVI $396 17 payments
  2. ARISTADA Cns $349 14 payments
  3. ARISTADA Cns $349 14 payments
  4. VRAYLAR $329 20 payments
  5. ARISTADA Cns $317 12 payments
  6. ARISTADA Cns $317 12 payments
  7. ABILIFY MAINTENA $196 9 payments
  8. APLENZIN $119 6 payments
  9. REXULTI Psychiatry $115 6 payments
  10. REXULTI Psychiatry $109 5 payments
  11. Other $1,460 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

82

Median for Psychiatry & Neurology: 100

Drug cost

$1,345

Median for Psychiatry & Neurology: $2,986

Branded share of claims

0%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 31 $498
Divalproex Sodium Generic 22 $304
Haloperidol Generic 18 $286
Hydroxyzine Hcl Generic 11 $258

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ARISTADA
  • Alkermes, Inc. $104
$104 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $57
$57 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $53
$53 — —
ABILIFY ASIMTUFII
  • Lundbeck LLC $22
  • Otsuka America Pharmaceutical, Inc. $10
$33 — —
SUBLOCADE
  • Indivior Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record